Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;28(3):1056-1081.
doi: 10.1111/ene.14642. Epub 2020 Dec 24.

Minocycline in neurodegenerative and psychiatric diseases: An update

Diego Romero-Miguel  1 , Nicolás Lamanna-Rama  1 , Marta Casquero-Veiga  1   2 , Vanessa Gómez-Rangel  1 , Manuel Desco  1   2   3   4 , María Luisa Soto-Montenegro  1   2
Affiliations
Free article
Review

Minocycline in neurodegenerative and psychiatric diseases: An update

Diego Romero-Miguel et al. Eur J Neurol. 2021 Mar.
Free article

Abstract

Background and purpose: Minocycline is a broad-spectrum antibiotic, effective as a chronic treatment for recurrent bacterial infections. Beyond its antibiotic action, minocycline also has important anti-inflammatory, antioxidant and antiapoptotic properties. Its efficacy has therefore been evaluated in many neurodegenerative and psychiatric diseases that have an inflammatory basis. Our aim was to review preclinical and clinical studies performed in neurological and psychiatric diseases whose treatment involved the use of minocycline and thereby to discern the possible beneficial effect of minocycline in these disorders.

Methods: Completed and ongoing preclinical studies and clinical trials of minocycline for both neurodegenerative diseases and psychiatric disorders, published from January 1995 to January 2020, were identified through searching relevant databases (https://www.ncbi.nlm.nih.gov/pubmed/, https://clinicaltrials.gov/). A total of 74 preclinical studies and 44 clinical trials and open-label studies were selected.

Results: The results of the nearly 20 years of research identified are diverse. While minocycline mostly proved to be effective in animal models, clinical results showed divergent outcomes, with positive results in some studies counterbalanced by a number of cases with no significant improvements. Specific data for each disease are further individually described in this review.

Conclusions: Despite minocycline demonstrating antioxidant and anti-inflammatory effects, discrepancies between preclinical and clinical data indicate that we should be cautious in analyzing the outcomes. Improving and standardizing protocols and refining animal models could help us to determine if minocycline really is a useful drug in the treatment of these pathologies.

Keywords: inflammation; minocycline; neurodegenerative diseases; oxidative stress; psychiatric disorders.

PubMed Disclaimer

References

REFERENCES

    1. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337-352.
    1. Zhang L, Zhao J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1103-1111.
    1. Garrido-Mesa N, Zarzuelo A, Gálvez J. What is behind the non-antibiotic properties of minocycline? Pharmacol Res. 2013;67(1):18-30.
    1. Kohno M, Link J, Dennis LE, et al. Neuroinflammation in addiction: a review of neuroimaging studies and potential immunotherapies. Pharmacol Biochem Behav. 2019;179:34-42.
    1. Kim JW, Hong JY, Bae SM. Microglia and autism spectrum disorder: overview of current evidence and novel immunomodulatory treatment options. Clin Psychopharmacol Neurosci. 2018;16(3):246-252.

Publication types

MeSH terms